Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 99-109

  Kinsella, Timothy J ^a,c   Kunugi, Keith A ^a   Vielhuber, Kathleen A ^a   Potter, David M ^a   Fitzsimmons, Michael E ^b   Collins, Jerry M ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 IODO 2 PYRIMIDINONE 2' DEOXYRIBOSE; ALLOPURINOL; ANTINEOPLASTIC AGENT; IDOXURIDINE; ISOVANILLIN; MENADIONE; PRODRUG; PYRIMIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG DNA BINDING; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CYTOSOL; LIVER METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIZATION; XENOGRAFT;

ANIMALS; DNA; FEMALE; HUMANS; IDOXURIDINE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PRODRUGS; PYRIMIDINE NUCLEOSIDES; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0031931512     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Efange, S. M. N., Alessi, E. M., Shih, H. C., Cheng, Y-C., and Bardos, T. J. Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-halo-2-pyrimidinone-2′-deoxyribonucleosides. J. Med. Chem., 28: 904-910, 1985.
2. Lewandowski, G. A., Grill, S. P., Fisher, M. H., Dutschman, G. E., Efange, S. M. N., Bardos, T. J., and Cheng, Y-C. Anti-herpes simplex virus activity of 5-substituted 2-pyrimidinone nucleosides. Antimicrob. Agents Chemother., 33: 340-344, 1989.
3. Lewandowski, G. A., and Cheng, Y-C. Mechanism and mode of action of 5-iodo-2-pyrimidinone 2′-deoxyribonucleoside, a potent antiherpes simplex virus compound, in herpes simplex virus-infected cells. Mol. Pharmacol., 39: 27-33, 1990.
4. Chang, C-N., Doong, S-L., and Cheng Y-C. Conversion of 5-iodo-2-pyrimidinone-2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase: implications in hepatotropic drug design. Biochem. Pharmacol., 43: 2269-2273, 1992.
5. Kinsella, T. J., Kunugi, K. A., Vielhuber, K. A., McCulloch, W., Liu, S-H., and Cheng, Y-C. An in vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. Cancer Res., 54: 2695-2700, 1994.
6. Miller, E. M., Fowler, J. F., and Kinsella, T. J. Linear quadratic analysis of radiosensitization by halogenated pyrimidines: radiosensitization of human colon cancer cells by IUdR. Radiat. Res., 131: 81-89, 1992.
7. Miller, E. M., Kunugi, K. A., and Kinsella, T. J. Effects of 5′-aminothymidine and leucovorin on the radiosensitization by iododeoxyuridine in human colon cancer cells. Clin. Cancer Res., 1: 407-416, 1995.
8. Rodriguez, R., Ritter, M. A., Fowler, J. F., and Kinsella, T. J. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int. J. Radiat. Oncol. Biol. Phys., 29: 105-113, 1994.
9. Kinsella, T. J., Glennon, M. C., Kunugi, K. A., and Lindstrom, M. J. In vivo modulation of iododeoxyuridine metabolism and incorporation into cellular DNA by 5′-amino-5′-deoxythymidine in normal mouse tissues and two human colon cancer xenografts. Clin. Cancer Res., 2: 981-989, 1996.
10. Chang, A. E., Collins, J. M., Speth, P. A. J., Smith, R., Walton, L., Begley, M. G., Glatstein, E., and Kinsella, T. J. A Phase I study of intra-arterial iododeoxyuridine in patients with colorectal liver metastases. J. Clin. Oncol., 7: 662-668, 1989.
11. McGinn, C. J., Kunugi, K. A., Tutsch, K. D., Feierabend, C., Alberti, D., Lindstrom, M. J., Wilding, G., Arzoomanian, R. Z., and Kinsella, T. J. Leucovorin modulation of iododeoxyuridine radiosensitization: a Phase I study. Clin. Cancer Res., 2: 1299-1305, 1996.
12. Sullivan, F. J., Herscher, L. L., Cook, J. A., Smith, J., Steinberg, S. M., Epstein, A. H., Oldfield, E. H., Goffman, T. E., Kinsella, T. J., Mitchell, J. B., and Glatstein, E. National Cancer Institute (Phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: encouraging results in anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys., 30: 583-590, 1994.
13. Robertson, J. M., Sondak, V. K., Weiss, S. A., Sussman, J. J., Chang, A. E., and Lawrence, T. S. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. Int. J. Radiat. Oncol. Biol. Phys., 31: 87-92, 1995.
14. Baker, B. R., and Wood, W. F. Irreversible enzyme inhibitors II. On the mode of phenyl binding of 9-phenylguanine to guanine deaminase and xanthine oxidase. J. Med. Chem., 10: 1101-1105, 1967.
15. Yoshihara, S., and Tatsumi, K. Kinetic and inhibition studies on reduction of diphenyl sulfoxide by guinea pig liver aldehyde oxidase. Arch. Biochem. Biophys., 249: 8-14, 1986.
16. Beedham, C. Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog. Med. Chem., 24: 85-127, 1987.
17. Adkins, W. K., and Taylor, A. E. Role of xanthine oxidase and neutrophils in ischemia reperfusion injury in rabbit lung. J. Appl. Physiol., 69: 2012-2018, 1990.
18. Speth, B. A. J., Kinsella, T. J., Chang, A. E., Klecker, R. W., Jr., Belanger, K., and Collins, J. M. Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver. Clin. Pharmacol. Ther., 44: 369-375, 1988.
19. Knol, J. A., Walker, S. C., Robertson, J. M., Yang, Z., DeRemer, S., Stetson, P. L., Ensminger, W. D., and Lawrence, T. S. Incorporation of 5-bromo-2′-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Cancer Res., 55: 3687-3691, 1995.
20. Milliken, G. E., and Johnson, D. E. The Analysis of Messy Data: Designed Experiments, Vol. 1, pp. 32-33. New York: Van Nostrand-Reinhold, 1984.
21. SAS Institute, Inc. SAS/STAT User's Guide, Version 6. Cary, NC: SAS Institute, Inc., 1989.
22. Belanger, K., Collins, J. M., and Klecker, R. W., Jr. Technique for detection of DNA nucleobases by reverse-phase high performance liquid chromatography optimized for quantitative determination of thymidine substitution by iododeoxyuridine. J. Chromotogr., 417: 57-63, 1987.
23. Pichard, L., Fabre, L., Fabre, G., Domergue, J., Aubert, B. S., Mourad, G., and Maurel, P. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos., 18: 595-606, 1990.
24. Fornace, A. J., Jr., Dobson, P. P., and Kinsella, T. J. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int. J. Radiat. Oncol. Biol. Phys., 18: 873-878, 1990.
25. Iliakis, G., Kurtzman, S., Panatelias, G., and Okayasu, R. Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing. Radiat. Res., 119: 286-304, 1989.
26. Lawrence, T. S., Davis, M. N., Maybaum, J., Stetson, P. L., and Ensminger, W. D. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat. Res., 123: 192-198, 1990.
27. Schultz, C. J., Gaffney, D. K., Lindstrom, M., Kinsella, T. J. Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: mechanistic implications and clinical relevance. Cancer J. Sci. Am., 1: 151-161, 1995.
28. Kinsella, T. J., Collins, J., Rowland, J., Klecker, R., Wright, D., Katz, D., Steinberg, S. M., and Glatstein, E. Pharmacology and Phase I/II study of continuous intravenous infusions of iododeoxyuridine (IdUrd) and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J. Clin. Oncol., 6: 871-879, 1988.
29. Fowler, J. F., and Kinsella, T. J. The limiting radiosensitization of tumors by S-phase sensitizers. Br. J. Cancer, 74: 5294-5296, 1996.
30. Ritter, M. A. New approaches to cell kinetics in human tumors. Curr. Prob. Cancer, 27: 325-328, 1993.
31. Cook, J. A., Glass, J., Lebovics, R., Bobo, H., Delaney, T. F., Glatstein, E., and Mitchell, J. B. Measurement of thymidine replacement in patients with high-grade gliomas, head and neck tumors and high-grade sarcomas after continuous infusions of 5-iodo-deoxyuridine. Cancer Res., 52: 719-725, 1992.
32. Lawrence, T. S., Davis, M. A., McKeever, P. E., Maybaum, J., Stetson, P. L., Normolle, D. P., and Ensminger, W. D. Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radio-sensitization in human colon cancer cells in vitro and in vivo. Cancer Res., 51: 3900-3905, 1991.
33. O'Dwyer, P. J., King, S. A., Hoth, D. F., and Leyland-Jones, B. Role of thymidine in biochemical modulation: a review. Cancer Res., 47: 3911-3919, 1987.
34. Coughlan, M. P. In: M. P. Coughlan, (ed.). Molybdenum and Molybdenum-containing Enzymes, pp. 169-185. Oxford, United Kingdom: Pergamon Press, 1980.
35. Hille, R., and Massy, V. In: T. P. Spiro (ed.). Molybdenum Enzymes, pp. 443-518. New York: Academic Press, 1985.
36. Krenitsky, T. A., Tuttle, J. V., Cattau, E. L., and Wang, P. A comparison of the distribution and electron acceptor specificities of xanthine oxidase and aldehyde oxidase. Comp. Biochem. Physiol., 49: 687-692, 1974.